✦ LIBER ✦

1055 ANTIVIRAL ACTIVITY OF ANA598, A POTENT NON- NUCLEOSIDE POLYMERASE INHIBITOR, IN CHRONIC HEPATITIS C PATIENTS

✍ Scribed by Lawitz, E.; Rodriguez-Torres, M.; DeMicco, M.; Nguyen, T.; Godofsky, E.; Appleman, J.; Rahimy, M.; Crowley, C.; Freddo, J.

Book ID: 122449045
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 45 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(09)61057-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preclinical pharmacokinetics and metabol

Preclinical pharmacokinetics and metabolism of a potent non-nucleoside inhibitor of the hepatitis C virus NS5B polymerase

✍ Giuliano, C.; Fiore, F.; Di Marco, A.; Padron Velazquez, J.; Bishop, A.; Bonelli 📂 Article 📅 2005 🏛 Informa plc 🌐 English ⚖ 303 KB

Antiviral activity of the hepatitis C vi

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1–infected patients

✍ Frank Wagner; Robert Thompson; Constantino Kantaridis; Paul Simpson; Philip J. F 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 599 KB

More effective and better-tolerated therapies are needed for chronic hepatitis C virus (HCV) infection. Among the direct-acting anti-HCV agents in development is the nonstructural 5B protein (NS5B polymerase) non-nucleoside inhibitor filibuvir. We investigated the antiviral activity, pharmacokinetic

92 SAFETY, TOLERABILITY AND ANTIVIRAL AC

92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION

✍ E. Lawitz; C. Cooper; M. Rodriguez-Torres; R. Ghalib; R. Lalonde; A. Sheikh; B. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOT

866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C

✍ Marcellin, P.; Popa, S.; Streinu-Cercel, A.; Boyer, N.; Dospinoiu, D.; Patat, A. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 57 KB

[50] ANTIVIRAL ACTIVITY OF THE NON-NUCLE

[50] ANTIVIRAL ACTIVITY OF THE NON-NUCLEOSIDE POLYMERASE INHIBITOR, HCV-796, IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2b IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV

✍ S.A. Villano; D. Raible; D. Harper; J. Speth; P. Chandra; P. Shaw; G. Bichier 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Robust antiviral activity of R1626, a no

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C

✍ Stuart K. Roberts; Graham Cooksley; Gregory J. Dore; Richard Robson; David Shaw; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 511 KB

The nucleoside analog R1479 is a potent and highly selective inhibitor of nonstructural protein 5B-directed hepatitis C virus (HCV) replication in vitro. R1626, a tri-isobutyl ester prodrug of R1479, was developed to increase bioavailability and improve antiviral activity. A multicenter, observer-bl